Our Newest Client Increased 229% in One Month! – This and Other Featured Opportunities on NAI500

NAI500
Published on: March 4, 2019
Author: Rebecca Hung

NAI500 is excited to introduce three companies on our growing online investor platform, www.NAI500.com. Visit their profiles below to learn what opportunities they bring.

 

The Yield Growth Corp (CSE:BOSS)

Yield Growth developments and acquires wellness products infused with hemp root oil and sell them to consumers and licenses them to businesses under Urban JuveTM, a modern, Ayurveda-inspired wellness brand. Urban JuveTM is focused on the nourishment, rejuvenation and transformation of the body from the inside out. Urban JuveTM inspires wellness-conscious consumers to #findyourjuve with personalized and carefully crafted, hemp root oil infused cosmeceutical and therapeutic products. Yield Growth also offer business development services to new businesses.

Company Highlights

  • Proven Management Team
  • International Licensing Strategy
  • Robust Design Platform
  • Regulatory Expertise
  • Signed Transaction for Rights to Urban Juve brand
  • Pricing Model Complete
  • Unique, Proprietary
  • Formulations & Methods
  • Production Underway
  • e-Commerce Platform

Click here to visit the company’s NAI500 profile to review their company background, recent press releases, latest presentation and fact sheet, investment highlights, projects and management team.


Beleave Inc (CSEBE)

Beleave is a vertically-integrated Canadian cannabis company headquartered in Oakville, Ontario, that operates streamlined facilities throughout Canada to cultivate high-quality cannabis flower, oil, and extracts with funded capacity in excess of 150,000 kg per year. Fully-licensed to cultivate and sell medical and recreational cannabis, Beleave is leading the way through research partnerships with universities to bridge the gap between science and tradition and to develop pharma-grade extracts and derivatives. Beleave is currently developing new product lines for October 2019 as the recreational market is expected to allow for food and beverage-based cannabis products.

Company Highlights:

Production Capacity (Total production capacity 1,731,500 SQ FT at 2020)

  • Hamilton Indoor Production – 14,500 SQ FT- open now
  • London Greenhouse Production – 250,000 SQ FT – early 2019
  • London Outdoor Production – 600,000 SQ FT – early 2019
  • British Columbia Indoor Production – 867,000 SQ FT – mid-late 2019

Product Development

  • Patenting Solubility
  • Solving Bio-Availability
  • Patenting Extraction

Sales and Distribution

  • Provincial supply agreements with access to over 55% of the Canadian population
  • Strategy to capitalize on international opportunities- undertaking negotiations to supply major EU and Colombia markets
  • Diversified house of brands, able to serve large and niche markets alike

House of Brands

  • Authentic brands that stand out with creative marketing, attractive packaging and memorable online and in-store buying experiences for highly targeted groups of individuals

Click here to visit the company’s NAI500 profile to review their company background, recent press releases, latest presentation and fact sheet, investment highlights, projects and management team.


Alzex Biomedical Group

Alzex is a collaboration of researchers, scientists, and investors that have developed and patented precision therapeutics for the treatment of Alzheimer’s and other neurological diseases. Their North American headquarters is located in Vancouver B.C with their laboratories located in France (Normandy).

Company Highlights:

  • The French partner VFP Therapies has developed innovative chemical entities which are improved prodrugs called Bioprecursors: they have the ability to easily go through the BBB and selectively act on specific receptors to induce therapeutic effects.
  • Alzex currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineer and research institute.
  • “Spending on care for people alive in the U.S. right now who will develop the affliction is projected to cost $47 trillion.” – Another Alzheimer’s Drug Fails as Lilly, Astra Halt Tests, Bloomberg.
    Currently conducting preclinical trials and expect to enter phase 1 in one to two years
  • Potential licensing arrangement opportunities for big pharmaceutical companies
  • Has potential to be applied to other brain diseases such as Parkinson’s, dementia, schizophrenia, cancer, etc.

Click here to visit the company’s NAI500 profile to review their company background, recent press releases, latest presentation and fact sheet, investment highlights, projects and management team.

Biotechnology Cannabis Life Science